US stocks
Oct 28, 2026

Genmab jumps more than 25% intraday to a record high as U.S. biotech stocks advance

Genmab rose more than 25% during intraday trading and hit a record high, according to MSX.COM data. The move came after the biotech company released updated results from its Phase III LiGeR-HN1 study of Petosemtamab, showing that the combination therapy reduced the risk of death by 50% in patients with head and neck squamous cell carcinoma. Other U.S.-listed biotech names also moved higher. Twist Bioscience gained more than 9%, Recursion Pharmaceuticals climbed more than 8%, and Moderna rose more than 4%. The session reflected broad strength across the U.S. biotechnology segment.

470
Genmab jumps more than 25% intraday to a record high as U.S. biotech stocks advance
Anthropic
Oct 28, 2026

Anthropic says Claude is now used across drug R&D, targets 2028 human trial for rare muscle disease program

Anthropic has outlined early drug-development work involving Claude across six organizations and, for the first time, disclosed its acquisition of Mithril Medicine, a tiny biotech that had only one full-time employee before the deal. The company said Claude is being used in tasks ranging from molecule design and manufacturing record review to IND drafting, investment evaluation, and clinical planning. Anthropic also said Mithril is developing two therapies for congenital muscular dystrophy, with the LAMA2-CMD program targeting a human trial by the end of 2028 and an αDG program aiming for 2029. For now, the evidence remains preclinical, limited to lab and mouse data. The company described several partner case studies. Generate:Biomedicines used Claude-assisted agents to redesign a CAR-T signaling segment, producing a version about 70% shorter with roughly 10x receptor expression in lab tests. Divergence Labs used Claude to generate about 35,000 antibody designs for food allergy work in roughly a month, using about 2,750 GPU hours. Enveda reported faster review of batch records and drafting of an IND Module 2 summary, while The Column Group and Bristol Myers Squibb used Claude for target evaluation and early clinical planning. Anthropic said these results are based largely on partner technical reports and preprints that have not gone through peer review, and noted that the trial timelines are goals rather than promises.

540
Anthropic says Claude is now used across drug R&D, targets 2028 human trial for rare muscle disease program
OpenAI
Oct 22, 2026

Former OpenAI science lead Kevin Weil launches AI drug discovery startup with $215 million funding

Kevin Weil, a former science leader at OpenAI, has started a new company focused on using artificial intelligence to speed up key stages of drug development. According to Bloomberg, the startup has already raised $215 million. Weil previously worked at OpenAI on applications of AI in scientific research, linking his new venture to his earlier work in the field. The brief announcement did not disclose the company’s name, investors, or a more detailed product roadmap, but it identified drug research acceleration as the core objective. The funding size places the launch among the larger early financing rounds tied to AI-driven science and biotech efforts.

670
Former OpenAI science lead Kevin Weil launches AI drug discovery startup with $215 million funding
Hong Kong stocks
Oct 22, 2026

Hong Kong stocks close lower as semiconductor and biotech shares fall

Hong Kong stocks finished lower, with broad weakness across technology, semiconductor, and biotech names, according to market data cited by Odaily. The Hang Seng Index closed down 3.03%, while the Hang Seng Tech Index fell 5.03%. Sector performance was led lower by tech stocks, the semiconductor supply chain, and biotechnology shares. Among individual names, Lenovo Group (00992.HK) fell nearly 11%, Hua Hong Semiconductor (01347.HK) dropped 9.5%, and WuXi Biologics (02269.HK) lost 8.4%. Alibaba (09988.HK) also declined more than 6% by the close. The move capped a weaker session for Hong Kong equities, with losses concentrated in growth-oriented and sector-heavy names highlighted in the market data.

730
Hong Kong stocks close lower as semiconductor and biotech shares fall
Anthropic
Oct 21, 2026

Claude Science designs protein binders targeting deadly scorpion neurotoxin

Anthropic’s Claude has independently designed protein binders aimed at a deadly scorpion neurotoxin, according to Techub, citing The Decoder. The report said more than 318,000 designs were generated, with 211 of them selected for laboratory testing. Of those, 17 met the required benchmark. The two strongest candidates were found to bind very tightly to the Cn2 toxin from a Mexican scorpion. The report did not say the work had already produced a usable treatment. It added that whether these binders can actually function as an antivenom still needs to be verified. The result points to a lab-tested screening outcome rather than a confirmed medical application at this stage.

790
Claude Science designs protein binders targeting deadly scorpion neurotoxin
U.S. stocks
Oct 20, 2026

U.S. optical networking and compute cloud stocks fall, while biotech names post gains

U.S. stocks tied to optical networking and compute cloud trading moved lower on Oct. 20, according to market data from BIT (Bit.com), while biotech shares mostly advanced. In optical networking, Lumentum fell 2.77%, Corning lost 2.02%, Coherent dropped 3.67%, Applied Optoelectronics slid 5.06%, Ciena declined 2.07%, Broadcom edged down 0.25%, and Marvell Technology fell 1.75%. Compute cloud-related names also traded lower. Oracle fell 1.18%, CoreWeave lost 2.78%, Nebius dropped 3.16%, IREN declined 4.22%, and Applied Digital fell 2.52%. Biotech stocks moved in the opposite direction. Eli Lilly rose 2.21%, Johnson & Johnson gained 1.15%, Moderna added 0.73%, Novo Nordisk rose 1.09%, and AbbVie gained 1.35%, while Merck was unchanged. In space-related stocks, SpaceX fell 1.71%, Rocket Lab lost 1.82%, Planet Labs declined 1.18%, AST SpaceMobile dropped 2.46%, and Intuitive Machines fell 2.14%.

640
U.S. optical networking and compute cloud stocks fall, while biotech names post gains
Biocytogen
Oct 20, 2026

Biocytogen Puts a Million Verified Antibody Sequences on the Shelf With RenSuper Workstation

Biocytogen launched its RenSuper Workstation in May 2026, giving drug developers a way to search candidate antibodies by target type, epitope features, functional requirements, and physicochemical properties. What sets the platform apart, according to the source article, is the inventory behind it: more than 1 million fully human antibody sequences derived from real immune responses in live mice rather than algorithmic generation. Each sequence has already gone through binding validation, affinity measurement, specificity assessment, and key functional testing. The article traces that database back to founder Shen Yuelei, who started Biocytogen in the U.S. in 2008 and established the China business in 2009. After beginning with custom gene knockout mouse services, the company shifted in 2015 toward a "CRO + product" model and later built the RenMice platform. A 2019 breakthrough allowed the company to replace mouse antibody variable-region genes with human counterparts, enabling direct production of fully human antibodies. The report argues that the antibody library is not just a product but the front end of a broader business loop linking antibody licensing, humanized mouse models, and preclinical pharmacology services. Financial figures cited in the piece show revenue of 13.79 billion yuan in 2025 and 940 million yuan in the first half of 2026, with gross margin reaching 76.2% in the latest reported half-year period.

600
Biocytogen Puts a Million Verified Antibody Sequences on the Shelf With RenSuper Workstation
AstraZeneca
Oct 15, 2026

AstraZeneca teams up with insitro on AI drug discovery deal worth up to $1.86 billion

AstraZeneca has entered an AI drug discovery partnership with biotech company insitro, in a deal valued at up to $1.86 billion. Techub, citing Crypto Briefing, reported that the agreement is aimed at using artificial intelligence to speed up the drug discovery process. The partnership brings together a major pharmaceutical company and an AI-focused biotech firm at a time when the use of machine learning in life sciences continues to draw attention. The report also said the collaboration could reshape industry dynamics, though no additional terms were disclosed in the source summary. The announcement centers on the size of the deal, the companies involved, and the role AI is expected to play in accelerating early-stage drug development.

750
AstraZeneca teams up with insitro on AI drug discovery deal worth up to $1.86 billion
Total 41 items
Go topage